Eylea
(Aflibercept)ApprovedProtein / enzyme
RegeneronAflibercept is used to treat eye diseases caused by abnormal blood vessel growth, such as wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. It works by blocking signals that cause these harmful blood vessels to form and leak fluid into the eye.[2] Eylea is currently approved and in use across 23 indications[4].[1]
Eylea is one of 245 small molecule programs targeting Diabetic Macular Edema. It is currently in Approved.
23
Indications
340
Total Trials
23
Active Trials
244
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 22 indications
Competition
Competitive Landscape
63 competitors in Cataract
#DrugCompanyPhaseTrials
1Avelox
BayerApproved
Decadron
AAspen Global Incorporated
Approved
Bromday
BBausch Health Americas, Inc.
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Toradol
RocheApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Voltaren
NovartisApproved
Cipro
BayerApproved
Eylea
RegeneronApproved
Versed
CConrado Roberto Hoffmann Filho
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Q3 2026
Phase 2Active, not recruiting
Diabetic Macular Edema
NCT06116916
Phase 2Active, not recruiting
Age-Related Macular Degeneration
NCT06116890
Post-ApprovalNot yet recruiting
Cataract
NCT07301775
Clinical
Trials by Indication[1]
Diabetic Macular Edema32 trials
Show 29 more trials
Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema
Enrolling by invitation·—·N/A·NCT07338097·116 enrolled
Age-Related Macular Degeneration23 trials
Show 20 more trials
Effect of Aflibercept on Human Corneal Endothelial Cells in Neovascular Age-Related Macular Degeneration
Completed·—··NCT03313401·34 enrolled
Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration
Completed·—·Phase 3·NCT02157077·90 enrolled
Wet Age-Related Macular Degeneration13 trials
Show 10 more trials
Metastatic Colorectal Cancer11 trials
Show 8 more trials
Retinal Vein Occlusion11 trials
Show 8 more trials
Assessment Of Peri-papillary Retinal Nerve Fiber Layer Thickness In Patients With Unilateral Branch Retinal Vein Occlusion
Completed·—·N/A·NCT06146309·60 enrolled
63 more indications
Efficacy and Safety8 trials
Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen
Completed·SSpanish Cooperative Group for the Treatment of Digestive Tumours (TTD)·Phase 2·NCT03279289·170 enrolled
Show 5 more trials
Treatment6 trials
Show 3 more trials
Home Monitoring in eAMD Treatment
Not yet recruiting·AAssociation for Innovation and Biomedical Research on Light and Image··NCT07340372·80 enrolled
Macular Degeneration5 trials
Show 2 more trials
Real World Outcomes of Intravitreal Anti-vascular Endothelial Growth Factors for Neovascular Age Related Macular Degeneration in Taiwan
Completed·—··NCT03324542·63 enrolled
Polypoidal choroidal vasculopathy4 trials
Show 1 more trial
Treatment of Polypoidal Choroidal Vasculopathy in Pachychoroid
Completed·AAzienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo·N/A·NCT04075188·17 enrolled
Wet Macular Degeneration4 trials
Choroidal Neovascularization4 trials
Neovascular AMD3 trials
Diabetic Retinopathy3 trials
Neovascular Glaucoma3 trials
Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated with Proton Therapy for a Large Choroidal Melanoma
Completed·—·Phase 3·NCT03172299·57 enrolled
nAMD2 trials
Randomized2 trials
Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1
Terminated·—·Phase 3·NCT03845049·16 enrolled
Safety and Efficacy2 trials
Proliferative Diabetic Retinopathy2 trials
High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes
Active, not recruiting·—·Phase 4·NCT07118670·40 enrolled
Colorectal Cancer2 trials
Intravitreal Injections2 trials
Retinopathy2 trials
Intravitreal Aflibercept Injection for Radiation Retinopathy Trial
Unknown status·—·Phase 2·NCT03085784·40 enrolled
Retinal Vasculitis2 trials
Ovarian Cancer2 trials
Carcinoma1 trial
Chemotherapy1 trial
MPA1 trial
Growth1 trial
ESS1 trial
Randomized Controlled Trial1 trial
AMD1 trial
Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD
Withdrawn·—·N/A·NCT02457026
Retinitis Pigmentosa1 trial
Corneal Neovascularization1 trial
Optical Coherence Tomography1 trial
Histoplasmosis1 trial
Treatment for Presumed Ocular Histoplasmosis
Unknown status·—·Phase 1/2·NCT01790893·40 enrolled
Vascular Disease1 trial
Monotherapy1 trial
Retinopathy of Prematurity1 trial
Locally-advanced Rectal Cancer1 trial
Prostate Cancer1 trial
Pancreatic Cancer1 trial
Lung Adenocarcinoma1 trial
Patients With Solid Tumors1 trial
Advanced Solid Malignancies1 trial
Inflammation1 trial
Lung Cancer1 trial
Treatment Outcome1 trial
Intravenous1 trial
Observational Study1 trial
Macular Edema1 trial
Biomarkers1 trial
Cataract1 trial
Unspecified8 trials
Regulatory
FDA Approval Timeline[5]
Nov 18, 2011
EYLEA
BLA BLA125387
Aug 18, 2023
EYLEA HD
BLA BLA761355
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Eylea drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Aflibercept. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]